MetaVia Inc. (NASDAQ: MTVA)

Sector: Healthcare Industry: Biotechnology CIK: 0001638287
Market Cap 2.09 Mn
P/B 0.33
P/E -0.13
P/S 0.00
ROIC (Qtr) -213.82
Div Yield % 0.00
Rev 1y % (Qtr) 0.00
Total Debt (Qtr) 79,000.00
Debt/Equity (Qtr) 0.01
Add ratio to table...

About

NeuroBo Pharmaceuticals, Inc. (NRBO) is a clinical-stage biotechnology company operating in the healthcare industry, specifically focused on developing and commercializing novel pharmaceuticals to treat cardiometabolic diseases. The company's primary business activities encompass research and development, preclinical developments, clinical trials, and raising capital. NeuroBo's operations span across various countries, including the United States. The company generates revenue through the development and commercialization of its primary products,...

Read more

Investment thesis

Bull case

  • Healthy cash reserves of 14.28M provide 180.72x coverage of short-term debt 79000, demonstrating strong liquidity position and minimal refinancing risk.
  • Strong tangible asset base of 14.77M provides 186.90x coverage of total debt 79000, indicating robust asset backing and low credit risk.
  • Tangible assets of 14.77M provide robust 6.05x coverage of other current liabilities 2.44M, indicating strong asset backing.
  • Strong cash position of 14.28M provides 5.85x coverage of other current liabilities 2.44M, indicating excellent liquidity.
  • Cash reserves of 14.28M provide robust 1.69x coverage of current liabilities 8.43M, indicating strong short-term solvency.

Bear case

  • Investment activities of (2000) provide weak support for R&D spending of 10.62M, which is -0x, suggesting potentially insufficient investment in innovation relative to other capital deployment.
  • The company's operating cash flow of (16.27M) shows concerning coverage of stock compensation expenses of 500000, with a -32.54 ratio indicating potential earnings quality issues.
  • Free cash flow of (16.27M) provides weak coverage of capital expenditures of 2000, with a -8135.50 ratio suggesting additional external financing needs for growth initiatives.
  • Operating earnings of (16.22M) show weak coverage of depreciation charges of 19000, with a -853.47 ratio indicating high capital intensity and potential reinvestment needs.
  • High financing cash flow of 8.88M relative to working capital of 6.21M, which is 1.43x suggests concerning dependence on external funding for operational needs.

Peer comparison

Companies in the Biotechnology
S.No. Ticker Company Market Cap P/E P/S Total Debt (Qtr)
1 SMMT Summit Therapeutics Inc. 1,204.25 Bn -1,306.67 0.00 0.01 Bn
2 ONC BeOne Medicines Ltd. 486.51 Bn 7,097.20 97.84 1.90 Bn
3 VRTX Vertex Pharmaceuticals Inc / Ma 122.05 Bn 30.87 10.17 1.85 Bn
4 REGN Regeneron Pharmaceuticals, Inc. 83.00 Bn 18.42 5.79 2.71 Bn
5 ARGX Argenx Se 50.78 Bn 33.71 26,480.10 -
6 ALNY Alnylam Pharmaceuticals, Inc. 43.66 Bn 139.17 11.76 2.97 Bn
7 BNTC Benitec Biopharma Inc. 43.61 Bn -941.82 0.00 0.00 Bn
8 INSM INSMED Inc 28.88 Bn -24.40 64.61 0.74 Bn

Industry comparisons

Current Valuation Value Ind Avg Percentile
EV to Assets EV to Assets -1.04 11.06
EV to Cash from Ops. EV/CFO 0.95 26.32
EV to Debt EV to Debt -194.97 762.61
EV to EBIT EV/EBIT 0.95 -13.49
EV to EBITDA EV/EBITDA 0.89 8.61
EV to Free Cash Flow [EV/FCF] EV/FCF 0.95 25.66
EV to Market Cap EV to Market Cap -7.38 203.37
EV to Revenue EV to Revenue 0.00 156.31
Price to Book Value [P/B] P/B 0.33 20.59
Price to Earnings [P/E] P/E -0.13 -0.88
Dividend Metrics Value Ind Avg Percentile
Dividend Coverage Ratio Div Coverage (Qtr) 0.00 -12.64
Dividend Payout Ratio % Div Payout % (Qtr) 0.00 0.17
Dividend per Basic Share Div per Share (Qtr) 0.00 0.01
FCF Dividend Payout Ratio % FCF Div Payout % (Qtr) 0.00 -0.14
Interest Coverage Int. cover (Qtr) 0.00 956.66
Growth Metrics Value Ind Avg Percentile
Capex Growth (1y) % Capex 1y % (Qtr) 88.24 7.87
Cash and Equivalents Growth (1y) % Cash & Equiv 1y % (Qtr) -34.11 753.48
Dividend Growth (1y) % Dividend Growth (1y) % 0.00 0.01
EBIAT Growth (1y) % EBIAT 1y % (Qtr) 41.53 -57.63
EBITDA Growth (1y) % EBITDA 1y % (Qtr) 40.34 8.83
EBIT Growth (1y) % EBIT 1y % (Qtr) 41.53 -67.21
EBT Growth (1y) % EBT 1y % (Qtr) 41.53 -23.74
EPS Growth (1y) % EPS 1y % (Qtr) 77.18 -7.02
FCF Growth (1y) % FCF 1y % (Qtr) 28.17 -40.48
Gross Profit Growth (1y) % Gross Profit Growth (1y) % 0.00 264.51
Liquidity Ratios Value Ind Avg Percentile
Asset Utilization Ratio Asset Util Ratio (Qtr) 0.00 0.14
Cash Payout Ratio Cash Payout (Qtr) 0.00 0.00
Cash Ratio Cash Ratio (Qtr) 1.69 3.92
Current Ratio Curr Ratio (Qtr) 1.74 7.33
Debt to Equity Ratio Debt/Equity (Qtr) 0.01 0.48
Interest Cover Ratio Int Coverage (Qtr) 0.00 956.66
Times Interest Earned Times Interest Earned (Qtr) 0.00 956.66
Profitability Value Ind Avg Percentile
EBITDA Margin % EBITDA Margin % 0.00 -17,888.70
EBIT Margin % EBIT Margin % 0.00 -18,246.34
EBT Margin % EBT Margin % 0.00 -19,108.08
Gross Margin % Gross Margin % 0.00 -10.30
Net Profit Margin % Net Profit Margin % 0.00 -19,056.96